Janet Freeman-DailyMay 5, 20191 minpCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC
Janet Freeman-DailyFeb 19, 20191 minEntrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors
Janet Freeman-DailyJan 17, 20193 minThinking about a “drug vacation” from crizotinib? Read this first!
Janet Freeman-DailyNov 5, 20181 minU.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC
Janet Freeman-DailyJun 15, 20181 minTP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP
Joyce HoeltingJan 5, 20174 minPatients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)